Biomaterials Translational is an international journal publishing research on the interface of translational medicine, biomaterials science, and engineering. The journal publishes original, high-quality, peer-reviewed papers, including original research articles, reviews, short reviews, short communications, editorials, viewpoints, and commentaries. Translational medicine is an interdisciplinary field that applies emerging technologies and sciences to the prevention, diagnosis, and treatment of human disease, focusing on animal disease models in the application of biomaterials for treatments. Thus, the journal highlights breakthrough discoveries in basic science and clinical application of biomaterials, as well as other significant findings related to the translation of biomaterials. The scope of the journal covers a wide range of physical, biological, and chemical sciences that underpin the design of biomaterials and the clinical disciplines in which they are used. This journal is oriented towards materials scientists and chemists who are interested in the clinical applications of novel biomaterials as well as clinicians from all disciplines who are interested in materials sciences.

Original articles will be considered for publication within, but not limited to, the following domains:

1. investigation of human biology and pathogenesis of diseases with potential applications of biomaterials in treatment
2. synthesis, characterization, and biomedical potential of metallic, ceramic, polymeric, composite, and hybrid biomaterials
3. physical, chemical, biological, pharmaceutical, and toxicological features of biomaterials
4. drug and gene delivery system design, with a focus on its application to disease conditions
5. short-term and long-term biocompatibility of biomaterials
6. in vivo disease models and the biology of the host response in the application of novel biomaterials
7. biomaterials design for modern diagnosis and therapeutic clinical practice (bioimaging, biosensing, biotherapy)
8. stem cell-biomaterial-based tissue engineering

Types of Publications

Biomaterial Translational does not accept manuscripts that have already been published or that are being considered for publication in another journal. The following is a list of the primary publication types: Original research articles, Reviews, Short reviews, Short communications, Editorials, Viewpoints, and Commentaries.

Peer Review Process

Experts rigorously and fully review all articles submitted for publication in Biomaterials Translational, including invited papers and spontaneous submissions. After receiving notification of the submission, the Editorial Board Member will be asked to do an editorial pre-check. After that, a peer review conducted by independent experts will be arranged to gather at least two review reports for each paper. Reviewers' reports gathered throughout the peer-review process will be made available to authors using the Editorial Manager (EM) platform in order to maintain transparency during the whole manuscript processing procedure. Before making a final decision, sufficient modifications from our authors will be required, along with a second round of peer review if needed. The Guest Editor, the Editorial Board Member, or the Editor-in-Chief make the ultimate decisions on whether to accept the final version. Accepted articles undergo typesetting and English editing will be announced online in the last. 

For more details, please reach Editorial Process.

Publishing Ethics

All participants in the journal Biomaterials Translational’s publishing process are asked to abide by the Committee on Publication Ethics (COPE) Best Practice Guidelines and Code of Conduct.

To ensure the inclusion of high-quality scientific works in the field of scholarly publication, the editors of this journal adhere to strict ethical norms and standards, as well as a rigorous peer-review process. Unfortunately, cases of data fabrication, image manipulation, plagiarism, false authorship credit, and other similar techniques do occur. We take such publishing ethics issues very seriously, and we will maintain a zero-tolerance attitude in such cases.

Any claims of publishing misconduct will be looked into by the in-house editors, who may also get in touch with the authors' organizations or funders if needed. If misconduct is discovered, the publication will be corrected or retracted. Biomaterials Translational requires authors to follow ethical publication norms.

Indexing & Archiving

The Editorial Team of Biomaterials Translational, a relatively new publication, is now working hard to have the journal listed in international databases. Additionally, the journal is included in or indexed by the following: 

Scopus 

PubMed Central

Language

The language of publication for this journal is English.

To guarantee that the academic substance of the article is completely understood by its potential readers, authors whose native language is not English might wish to have their manuscripts professionally edited prior to final submission.

Author Appeals

By emailing the journal's Editorial Office, authors can contest a rejection. A thorough explanation must be included in the appeal, along with specific answers to the reviewers' and/or editor's remarks. Only after a "reject and decline resubmission" decision may an appeal be filed, and it must be filed within three months of the decision date. The appeal will not be further considered if these requirements are not met. A chosen Editorial Board Member will receive the manuscript and associated data, including the referees' identities, from the Managing Editor. The consulted academic editor will be asked to offer an advisory opinion on the article, which could support the initial rejection decision, suggest acceptance, or suggest more peer review. The Editor-in-Chief will then confirm this choice. At this point, a rejection decision is definitive and cannot be changed.

Comments and Complaints

When readers have issues or grievances regarding published papers, they should first try to resolve them directly with the corresponding author before contacting the Editorial Office.

If contacting the authors is inappropriate, the authors did not respond, or the issues were not addressed, the Editorial Office may be notified. In order to investigate, address, or resolve any issues or complaints, the Editorial Office will work in tandem with the author or authors, the complainant, and the Editors-in-Chief or members of the Editorial Board.

Where appropriate, complaints, remarks, or requests for updates on the paper's or its review process's scholarly legitimacy, ethical, or legal issues will be looked into further. With the assistance of the Editorial Board and final approval from the Editor-in-Chief, the Editorial Office looks into any complaints, comments, or requests for updates about published papers. Final decisions regarding ethical issues are taken by the Editor-in-Chief or members of the Editorial Board, who are assisted by the Editorial Office in promoting adherence to the COPE's basic publication ethics principles. As needed, other individuals and organizations will be consulted, such as university administrators or subject-matter specialists. If there are legal ramifications to the complaint, legal help may be sought.

Criticism or personal remarks will not be accepted. Investigations are conducted into all complaints, even those that are anonymous. Insofar as it is appropriate and compliant with our internal protocols, the Editorial Office, any Editors-in-Chief, or other members of the Editorial Board shall make every effort to handle complaints in a secret manner upon request from complainants.

The Editors-in-Chief or members of the Editorial Board decide whether corrections, comments and replies, expressions of concern, or retractions should be made after an investigation and inform the authors of their decisions. Every change must adhere to our published paper updating policy.

Only if more information demonstrating concerns is provided will subsequent communication be taken into consideration if a complaint is deemed unfounded.

Until a final decision is made, complainants may not be informed of the investigation's progress; however, they will be informed if any updates are released. Editorial Board members and the Editorial Office are not required to provide more information. If communication is not deemed kind or pleasant, it will be terminated. It should be noted by readers who have grievances or concerns that investigations take time to complete.

Please use the contact form or the information below to contact the Editorial Office with any concerns. Along with information about the paper, please include information about the complaint, its scholarly, scientific, or academic validity, a synopsis of the main points and any other issues, a record of any previous correspondence with the authors, and a statement outlining any actual, potential, or perceived conflicts of interest.

Withdrawal Policy

A penalty fee would have to be paid if the author chose to withdraw an article after it had been accepted (but not yet published). It is not appropriate for writers to withdraw an article after it has been submitted for peer review; instead, they should do so only if they find serious problems or inconsistencies. After receiving confirmation of withdrawal from the Journal Editorial Office, the author considers the withdrawal process to be finished.

Advertising Policy

The publisher has the authority to approve all advertisements. Commercials have to abide by the applicable laws in the nation in which they are shown. For any questions, please contact editors@biomat-trans.com.

Privacy Statement

No other purpose or third party will be able to access the names and email addresses entered on this journal site; they will only be used for the purposes specified by this journal.

Copyright

Please note that the copyright of the content published in this journal belongs to the author(s) or the Chinese Medical Association. Authors will retain the copyright of the publication under Open Access, or they will be notified to sign a copyright transfer agreement during manuscript processing, which means that they consent to transfer the copyright in all versions of their article to the Chinese Medical Association. In the latter case, you will not be able to add a license to your work (including any earlier versions of it) unless you have the Chinese Medical Association's permission. 

Publishing Model

Hybrid. From January 2025, we (Biomaterials Translational) will endeavor to transfer into a hybrid journal. Authors will have two options to retain copyright for articles published under the open access option or to sign a copyright transfer agreement to transfer the copyright to the Chinese Medical Association which is the academic supporter of Biomaterials Translational. More can be reached at: Supports Open Access.

Organization 

The journal is sponsored by the Chinese Medical Association, published by the Chinese Medical Multimedia Press, and executed by Shanghai University.